title: [Alphacalcidol in the treatment of osteopenic syndrome in patients with bronchial asthma].
abstract: OBJECTIVE
  To assess effectiveness of alphacalcidol in the treatment of osteopenic syndrome in patients with bronchial asthma (BA).
  
  
  METHODS
  65 BA patients with low densitometric parameters of bone tissue density were examined for bone density, basic parameters of Ca-P metabolism and some markers of bone metabolism during 6-month therapy with alphacalcidol (alpha-D3-TEVA) in a dose 0.5-0.75 mcg/day.
  
  
  RESULTS
  All the patients after 6 months of therapy experienced pain relief, normalization of calcium-phosphorus metabolism, lower risk of broken bones. Their bone tissue increased its density.
  
  
  CONCLUSIONS
  Alphacalcidol has analgetic and antiresorptive properties. It effectively prevents and treats osteopenic syndrome in patients with bronchial asthma.
authors: E A
authors: EA
authors: Kochetkova
authors: B I
authors: BI
authors: Gel'tser
mesh_terms: D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000473:pathology; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000139:chemically induced / Q000188:drug therapy*; D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000097:blood; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D017553:Phosphorus Compounds / Q000097:blood; D011788:Quality of Life; D013577:Syndrome
chemical_list: D018927:Anti-Asthmatic Agents; D005938:Glucocorticoids; D006887:Hydroxycholecalciferols; D017553:Phosphorus Compounds; D002118:Calcium; C008088:alfacalcidol